Clinical Trial Update: A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing mezigdomide, bortezomib and dexamethasone (MEZVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in relapsed or refractory mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Mezigdomide (mezigdomide)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Celgene | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 3 | Status: RECRUITING